



Celgene Corporation
Investor Relations Department
86 Morris Avenue
Summit, NJ 07901
United States

[Visit IR website](#)
[Sign-up for e-mail alerts](#)

NASDAQ: CELG

Last Trade:	89.27
Trade Time:	4:00 PM ET Aug 15, 2018
Change:	-3.44 (3.711%)
Day Range	89.12 - 92.45
52-Week Range	74.13 - 147.17
Volume	6,697,789

Stock information is provided by eSignal,
stock charts provided by EDGAR Online.
Stock data is delayed approximately 20
minutes.

Company Profile

Celgene Corporation is a global biopharmaceutical company engaged in the discovery, development and commercialization of innovative therapies for the treatment of cancer and immune-inflammatory related diseases. Our portfolio of commercial products include REVLIMID®, VIDAZA®, THALOMID®, POMALYST®/IMNOVID®, ABRAXANE®, OTEZLA®, ISTODAX® and IDHIFA®. The drug candidates in our pipeline are at various stages of preclinical and clinical development. These cand... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- Jul 26, 2018*
[Celgene Reports Second Quarter 2018 Operating and Financial Results](#)
- Jul 23, 2018*
[Celgene Announces Phase III 'AUGMENT' Study of REVLIMID® in Combination with Rituximab \(R²\) for the Treatment of Patients with Relapsed/Refractory Indolent Lymphoma Met Primary Endpoint](#)
- Jul 10, 2018*
[Anti-PD-L1 Immunotherapy Plus ABRAXANE® Significantly Reduced the Risk of Disease Worsening or Death in Patients with Metastatic or Locally Advanced Triple Negative Breast Cancer in Phase III Impassion130 Study](#)
- Jul 9, 2018*
[Celgene and Acceleron Announce Luspatercept Achieved Primary and All Key Secondary Endpoints in Phase III 'BELIEVE' Study in Adults with Transfusion-Dependent Beta-Thalassemia](#)
- Jul 2, 2018*
[Celgene Corporation to Announce Second Quarter 2018 Results on July 26, 2018](#)

Financials [\[View all \]](#)

- Feb 7, 2018*
[Annual Report \(10-K\)](#)
- Apr 30, 2018*
[Proxy Statement \(DEF 14A\)](#)
- Jul 26, 2018*
[Quarterly Report \(10-Q\)](#)
- May 4, 2018*
[Quarterly Report \(10-Q\)](#)
- Oct 26, 2017*
[Quarterly Report \(10-Q\)](#)